A randomized, double-blind, placebo-controlled trial of Chinese herbal medicine capsules for the treatment of premature ovarian insufficiency
| Autor: | Xiaojing Cao, Xuchun Huang, Ji-ju Wang, Fei Ma, Jian Liu, Yuyan Zeng, Changqian Chen, Guangning Nie, Xiaoyun Wang |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Anti-Mullerian Hormone medicine.medical_specialty General Mathematics Treatment outcome MEDLINE Placebo-controlled study Capsules Primary Ovarian Insufficiency Premature ovarian insufficiency law.invention Double blind 03 medical and health sciences 0302 clinical medicine Double-Blind Method Ovarian Follicle Randomized controlled trial law Internal medicine medicine Humans 030212 general & internal medicine 030219 obstetrics & reproductive medicine Estradiol business.industry Applied Mathematics Ovary Obstetrics and Gynecology Treatment Outcome Female Follicle Stimulating Hormone business Drugs Chinese Herbal |
| Zdroj: | Menopause. 25:918-926 |
| ISSN: | 1530-0374 1072-3714 |
| DOI: | 10.1097/gme.0000000000001099 |
| Popis: | This study was conducted to evaluate the treatment effectiveness of Chinese herbal medicine capsules containing the Yangyin Shugan formula (YYSG) in premature ovarian insufficiency (POI).One-hundred forty-six women with POI participated in this stratified, randomized, double-blind, placebo-controlled clinical trial. Participants in two groups (n = 73 in each)-the YYSG group and control group-underwent treatment for 12 weeks. Outcome measures included the Chinese version Menopause-Specific Quality of Life questionnaire (CMS), serum levels of basal follicle-stimulating hormone (bFSH), basal estradiol, and anti-Mullerian hormone (AMH), the antral follicle count (AFC), and ovarian peak systolic velocity (PSV; cm/s).Treatment with YYSG significantly reduced the total scores of the CMS at the end of the 12th week with statistical significance (P 0.01); the vasomotor, psychosocial, physical, and sexual domains significantly improvement after treatment (P 0.01). Compared with the baseline hormone levels, YYSG markedly decreased the bFSH level with statistical significance (P 0.01) and improved the AMH level (P 0.01). Furthermore, YYSG greatly improved the participants' AFC and ovarian PSV, compared with placebo (P 0.01). There were no serious adverse events, and the safety indices of whole blood counts, renal function, and liver function were within the normal range, both before and after treatment.Treatment with YYSG was more effective than placebo for improving menopausal symptoms, basal hormone levels, and ovarian function in women with POI in Guangdong, China. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|